Evaluation of Comfort With Xibrom (Bromfenac Ophthalmic Solution)0.09% and Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Following Selective Laser Trabeculoplasty (SLT)
- First Posted Date
- 2009-01-26
- Last Posted Date
- 2009-06-10
- Lead Sponsor
- Bp Consulting, Inc
- Target Recruit Count
- 25
- Registration Number
- NCT00828477
- Locations
- 🇺🇸
Coburn-Kleinfeldt Eye Clinic, 3340 6 mile Rd Livonia, Michigan, United States
Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Phase 4
Completed
- Conditions
- Open-Angle GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2009-01-14
- Last Posted Date
- 2009-01-14
- Lead Sponsor
- Bp Consulting, Inc
- Target Recruit Count
- 140
- Registration Number
- NCT00822081
Randomized, Double Blind Trial of Bromfenac BID (0.09%) as an Adjunct to Argon Laser Therapy in the Treatment of Diabetic Macular Edema.
Phase 4
Completed
- Conditions
- Diabetic Macular Edema
- Interventions
- Drug: BromefenacDrug: Blink
- First Posted Date
- 2008-09-25
- Last Posted Date
- 2009-09-04
- Lead Sponsor
- Bp Consulting, Inc
- Target Recruit Count
- 50
- Registration Number
- NCT00758628
- Locations
- 🇺🇸
Retina Eye Associates of New York, 140 East 80th street New York, NY 10075, New York, United States
Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery
Phase 4
Completed
- Conditions
- Cataracts
- Interventions
- First Posted Date
- 2008-09-25
- Last Posted Date
- 2012-03-15
- Lead Sponsor
- Bp Consulting, Inc
- Target Recruit Count
- 49
- Registration Number
- NCT00758199
- Locations
- 🇺🇸
Altos Eye Physicians, Los Altos, California, United States
Comparison of Istalolâ„¢ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG)
Phase 4
Completed
- Conditions
- Ocular HypertensionOpen-Angle Glaucoma
- Interventions
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2008-12-04
- Lead Sponsor
- Bp Consulting, Inc
- Target Recruit Count
- 40
- Registration Number
- NCT00698945
- Locations
- 🇺🇸
North Bay Eye Associates, Inc., Petaluma, California, United States
Comparing Optical Coherence Tomography (OCT) and Visual Acuity Outcomes in Subjects Undergoing Cataract Surgery, Who Receive Xibrom Ophthalmic Solution and Standard Presurgical Care vs. Xibrom Ophthalmic Solution Plus Prednisolone Acetate 1% and Standard Presurgical Care
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2009-06-10
- Lead Sponsor
- Bp Consulting, Inc
- Target Recruit Count
- 200
- Registration Number
- NCT00698724
- Locations
- 🇺🇸
St. Luke's Cataract and Laser institute, Tarpon Springs, Florida, United States
Efficacy of PEG-400 and Systane Artificial Tears (Alcon) on Quality of Vision
- First Posted Date
- 2008-03-03
- Last Posted Date
- 2008-11-24
- Lead Sponsor
- Bp Consulting, Inc
- Target Recruit Count
- 40
- Registration Number
- NCT00627302
- Locations
- 🇺🇸
Ophthalmic Consultants of long Island, Rockville Centre, New York, United States
Bilateral, Masked Comparison of PEG-400 Based Artificial Tear and Systane for the Treatment of Dry Eye Signs, Symptoms and Visual Quality
- First Posted Date
- 2008-02-22
- Last Posted Date
- 2010-02-03
- Lead Sponsor
- Bp Consulting, Inc
- Target Recruit Count
- 70
- Registration Number
- NCT00622037
- Locations
- 🇺🇸
Florida Microsurgical Eye Institute, Boynton Beach, Florida, United States
Bilateral, Masked Comparison of PEG-400 Based Artificial Tear vs. Systane for Dry Eye Signs, Symptoms & Refractive Regression Associated With Myopic Laser in Situ Keratomilieusis (LASIK).
Phase 4
Completed
- Conditions
- Dry Eye Syndromes
- Interventions
- Drug: PEG- 400 based artificial tear
- First Posted Date
- 2008-02-22
- Last Posted Date
- 2009-09-21
- Lead Sponsor
- Bp Consulting, Inc
- Target Recruit Count
- 100
- Registration Number
- NCT00620893
- Locations
- 🇺🇸
Weill Cornell Medical Center, New York, New York, United States
Treatment of Acute Pseudophakic Cystoid Macular Edema: Bromfenac 0.09% Versus Diclofenac Sodium 0.1% Versus Ketorolac Tromethamine 0.5%
Phase 4
Completed
- Conditions
- Acute Pseudophakic Cystoid Macular Edema
- Interventions
- First Posted Date
- 2008-01-16
- Last Posted Date
- 2009-03-19
- Lead Sponsor
- Bp Consulting, Inc
- Target Recruit Count
- 166
- Registration Number
- NCT00595543
- Locations
- 🇺🇸
Soll Eye Associates, Philadelphia, Pennsylvania, United States
© Copyright 2025. All Rights Reserved by MedPath